跳至主要内容
临床试验/NCT01738399
NCT01738399已完成不适用

Influence of Coffee Consumption on Insulin Sensitivity in Overweight and Insulin Resistant Subjects.

National University Hospital, Singapore2 个研究点 分布在 1 个国家目标入组 128 人开始时间: 2012年4月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
128
试验地点
2
主要终点
Change in insulin sensitivity when compared to baseline as measured using the euglycemic hyperinsulinemic clamp.

研究概览

简要总结

The purpose of the study is to investigate the long-term (24 weeks) effects of coffee consumption on insulin sensitivity in insulin resistant individuals.

详细描述

Coffee is a major source of the phenolic acid chlorogenic acid and a substantial source of trigonelline, niacin, lignans magnesium, and potassium. Several of these compounds have been shown to improve glucose metabolism in animal models. Consumption of coffee was inversely associated with the risk of type-2 diabetes in prospective cohort studies across the world. Consumption of 3 to 4 cups of coffee per day was associated with an approximately 25% lower risk of type-2 diabetes. However, direct evidence of the efficacy of coffee to reduce blood glucose and insulin resistance parameters in humans from randomized trials is still lacking. In recent small trials of short duration (up to 6 weeks) coffee consumption increased levels of the insulin-sensitizing hormone adiponectin, but did not significantly improve insulin sensitivity These results suggest that a larger longer-term trial of the effects of coffee consumption on directly measured insulin sensitivity is warranted.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
35 Years 至 69 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects classified as being insulin-resistant in the screening visit. Subjects should have a non-diabetic fasting plasma glucose concentration (< 7.0 mM) and a HOMA-IR > 2.
  • The HOMA-IR was demonstrated as a reliable indicator of insulin resistance strongly correlated with values obtained by clamp (4). The cut-off value of the HOMA-IR was defined according to data obtained in the Singapore cohort. It corresponds to the 75th percentile of the population. The HOMA-IR cut-off was subsequently revised to ≥ 1.3 to increase recruitment rates.
  • Age: ≥ 35 to ≤ 69 years old
  • Body mass index : ≥ 22.5 to ≤ 35.4 kg/m2
  • Users of at least 1 cups of caffeinated coffee per day who are willing to be randomized to any of the interventions.
  • Subjects should be willing to stop consuming caffeinated soft drinks or supplements during the study and to drink coffee with non-dairy creamer.
  • Non-smokers (< 1 cigarette per week)
  • Participants have been weight stable for at least -8 weeks pre-ceding the screening visit (± 2.5 kgs).
  • Chinese, Malay and Indian ethnicity

排除标准

  • Subjects representing one or more of the following criteria are excluded from participation in the study:
  • Any condition/illness that may affect the study outcomes or would make participation potentially harmful such as pregnancy or breastfeeding, diabetes mellitus, heart disease, stroke, hypertension, malabsorption syndromes, GERD, a history of ulcer, clotting or bleeding disorders,allergy to the test beverage, allergy to insulin, according to a detailed medical history.
  • Participants who are allergic to foods may be excluded based on the investigator's discretion.
  • Participants consume > 2 alcoholic servings/day on a regular basis and > 8 caffeinated servings (based on tea and coffee)/day
  • Present drug abuse or use of medications that could interfere with the treatment including bronchodilators, quinolone antibiotics, monoamine oxidase inhibitors, anxiolytics, ranitidine, corticosteroids, growth hormone, anti-hypertensives. These conditions will be screened based on subject reporting. Participants will be asked to bring in their current medications at the time of screening, and these will be checked by the study-staff.
  • Subject is taking traditional medications, herbal or dietary supplements that may affect the study outcome in the opinion of the investigators.
  • Subject who cannot be expected to comply with the study procedures in the opinion of the investigators.
  • Currently participating or having participated in another clinical trial during the last 12 weeks prior to the beginning of this study.
  • Premenopausal women with self-reported irregular menstrual cycles or peri-menopausal women (participants who stopped getting their menses for less than 48 weeks ).

研究组 & 干预措施

Coffee

Experimental

Subjects take 4 cups of coffee mix per day for 24 weeks

干预措施: Coffee (Dietary Supplement)

Placebo

Placebo Comparator

Subjects take 4 cups of placebo per day for 24 weeks

干预措施: Placebo (Dietary Supplement)

结局指标

主要结局

Change in insulin sensitivity when compared to baseline as measured using the euglycemic hyperinsulinemic clamp.

时间窗: Baseline and 24 weeks

次要结局

  • Change in fasting plasma total adiponectin concentrations from baseline to 12 weeks(Baseline, 12 weeks)
  • Change in fasting plasma glucose concentration from baseline to 12 weeks(Baseline, 12 weeks)
  • Change in fasting plasma glucose concentration from baseline to 24 weeks(Baseline, 24 weeks)
  • Change in fasting plasma total adiponectin concentrations from baseline to 24 weeks(Baseline, 24 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Coffee and Metabolic Health Outcomes | 临床试验